Novel Biologic for Psoriasis Bests Methotrexate

Psoriasis responds substantially better to the novel monoclonal antibody briakinumab than to methotrexate, according to randomized trial results, but the drug has some serious side effects.The proportion of moderate-to-severe cases with at least a 75% improvement in Psoriasis Activity and Severity Index score after one year of treatment was 66.2% compared with just 23.9% on methotrexate (P0.001), Kristian Reich, MD, of Dermatologikum Hamburg, Germany, and colleagues found.Similarly, 63% of

Read more ...